Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of Evogliptin Added to Metformin and Dapagliflozin in Type 2 Diabetes
NCT04170998Phase 3Completed
- Sponsor
- Dong-A ST
- Start
- Jan 2020
- Primary completion
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of DA5221-B2 in type 2 diabetes mellitus (T2DM), sponsored by Dong-A ST. Started Jan 2020; status: completed.
02
Drugs
DA5221-B2
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT04170998.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04170998.